<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T06:17:07Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/14389" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/14389</identifier><datestamp>2026-10-18T21:14:22Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>The effect of rutin on ovarian ischemia-reperfusion injury in a rat model</dc:title><dc:creator>Nayki, Cenk</dc:creator><dc:creator>Nayki, Umit</dc:creator><dc:creator>Keskin Cimen, Ferda</dc:creator><dc:creator>Kulhan, Mehmet</dc:creator><dc:creator>Yapca, Omer Erkan</dc:creator><dc:creator>Kurt, Nezahat</dc:creator><dc:creator>Bilgin Ozbek, Aslı</dc:creator><dc:subject>inflammation</dc:subject><dc:subject>ischemia-reperfusion</dc:subject><dc:subject>Ovary</dc:subject><dc:subject>oxidative stress</dc:subject><dc:subject>rutin</dc:subject><dc:subject>Animals</dc:subject><dc:subject>Antioxidants</dc:subject><dc:subject>Female</dc:subject><dc:subject>Injections, Intraperitoneal</dc:subject><dc:subject>Interleukin-1beta</dc:subject><dc:subject>Malondialdehyde</dc:subject><dc:subject>Ovarian Diseases</dc:subject><dc:subject>Rats</dc:subject><dc:subject>Rats, Wistar</dc:subject><dc:subject>Reperfusion Injury</dc:subject><dc:subject>Tumor Necrosis Factor-alpha</dc:subject><dc:subject>cyclooxygenase 1</dc:subject><dc:subject>cyclooxygenase 2</dc:subject><dc:subject>glutathione</dc:subject><dc:subject>interleukin 1beta</dc:subject><dc:subject>malonaldehyde</dc:subject><dc:subject>rutoside</dc:subject><dc:subject>tumor necrosis factor</dc:subject><dc:subject>antioxidant</dc:subject><dc:subject>animal experiment</dc:subject><dc:subject>animal model</dc:subject><dc:subject>animal tissue</dc:subject><dc:subject>antiinflammatory activity</dc:subject><dc:subject>antioxidant activity</dc:subject><dc:subject>Article</dc:subject><dc:description>The effect of rutin on ovarian ischemia-reperfusion (I/R) injury was investigated in this experimental study. Eighteen Wistar albino female rats were divided into three groups as follows: I/R group (IRG; n = 6), 50 mg/kg rutin + I/R group (RG; n = 6), and a healthy control group scheduled for a sham operation (SG; n = 6). 2 h of ischemia and following 2 h of reperfusion were created in the IRG and RG by using a torsion model involving atraumatic vascular clips. Rutin, a flavonoid glycoside, was injected intraperitoneally at the dose of 50 mg/kg to RG group 1 h before reperfusion. Then, rats were euthanized and their ovaries were removed for biochemical and histopathological examination and also assessment of the gene expressions. IRG group had a significant increase in malondialdehyde (MDA) levels, in the expressions of tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β), and also in the activity of cyclooxygenase 2 (COX-2) unlike the significant decrease in total glutathione (tGSH) levels and the activity of COX-1 when compared to the SG group. However, rutin significantly decreased MDA levels, the expressions of TNF-α and IL-1β, and also the activity of COX-2 while it increased significantly tGSH levels and the activity of COX-1 in the RG group in comparison with the IRG group. Rutin ameliorated the I/R-induced ovarian injury in rats via its possible antioxidative and anti-inflammatory effects. © 2018, © 2018 Informa UK Limited, trading as Taylor &amp; Francis Group.</dc:description><dc:publisher>Taylor and Francis Ltd</dc:publisher><dc:date>2018</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/14389</dc:identifier><dc:identifier>https://doi.org/10.1080/09513590.2018.1450378</dc:identifier><dc:identifier>0951-3590</dc:identifier><dc:language>en</dc:language><dc:relation>Gynecological Endocrinology</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/14389</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>